title: Reversible opacification of a hydrophilic acrylic intraocular lens.
abstract: A 56-year-old woman with diabetic retinopathy and chronic myelogenous leukemia had phacoemulsification cataract removal and hydrophilic acrylic intraocular lens (IOL) (Akreos MI-60) implantation in both eyes. One month after surgery, significant IOL opacity and severe cystoid macular edema were observed in both eyes. After bilateral intravitreal injection of bevacizumab (Avastin) to control macular edema, central clearing of the IOL opacity was observed in both eyes. Two months after the injection, the IOL opacity had almost disappeared from both eyes. To our knowledge, this is the first case of early postoperative bilateral IOL opacity in a hydrophilic acrylic IOL cleared after anti-vascular endothelial growth factor (VEGF) intravitreal injection. The role of anti-VEGF therapy in clearing IOL opacification requires further investigation.
authors.affiliation: Department of Ophthalmology, Dongguk University, Ilsan Hospital, Koyang, Kyunggido, South Korea. choulyong@yahoo.co.kr
authors.forename: Choul Yong
authors.initials: CY
authors.lastname: Park
authors.forename: Roy S
authors.initials: RS
authors.lastname: Chuck
mesh_terms: D000180:Acrylic Resins; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D019654:Lens Implantation, Intraocular; D007910:Lenses, Intraocular; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D008875:Middle Aged; D018918:Phacoemulsification; D011475:Prosthesis Failure; D012075:Remission, Spontaneous; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000180:Acrylic Resins; D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab